Skip to main content
OpenTrials
Completed

NCT Number: NCT06390228

Impact of Hepatectomy on HCC Recurrence

Hepatectomy is the first option for the treatment of hepatocellular carcinoma(HCC) at CNLC Ib stage. HCC patients who undergo curative hepatectomy may experience varying remnant liver volumes and thus leads to different oncological outcomes.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hepatocellular Carcinoma Stage I Adenocarcinoma Carcinoma Carcinoma, Hepatocellular Digestive System Diseases Digestive System Neoplasms Disease Attributes Liver Diseases Liver Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Pathologic Processes Pathological Conditions, Signs and Symptoms Recurrence

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Anhui Provincial Hospital

Hefei, Anhui, 230001, China

About this study

Patients with hepatocellular carcinoma (HCC) who undergo curative hepatectomy may experience varying remnant liver volumes. The investigators aimed to evaluate whether the extent of liver resection has an effect on postoperative recurrence in HCC patients. A retrospective analysis was conducted on 197 patients who underwent hepatectomy for a solitary HCC lesion measuring ≥5 cm between January 2019 and June 2022. Patients were divided into major hepatectomy (MAH) group (n=70) and minor hepatectomy (MIH) group (n=127) based on the extent of liver resection. Recurrence-free survival (RFS) was compared between the two groups. Propensity score matching was employed to mitigate potential biases in this research.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • histologically confirmed solitary HCC with a size of ≥5 cm
  • Eastern Cooperative Oncology Group score of 0 or 1
  • preoperative indocyanine green retention rate at 15 minutes ≤15% and Child-Pugh A classification
  • no evidence of vascular invasion or extrahepatic disease.

Exclusion criteria

  • not diagnosed with HCC or had an HCC measuring <5 cm
  • had confirmed tumor metastases or macrovascular invasion based on radiological examinations
  • died within 90 days after surgery were excluded

Treatment and study plan

Major hepatectomy

Procedure

the extent of liver resection

Other names: minor hepatectomy

Primary outcomes

  1. recurrence-free survival

    Time frame: 2019.1-2023.8

    the time from the time of radical surgery to the time of HCC recurrence

Sponsors and collaborators

Lead sponsor

Anhui Medical University

Other

Collaborators

  • National Natural Science Foundation of China

Registry information

Official study title

Impact of Major Hepatectomy on Recurrence After Resection of Hepatocellular Carcinoma at China Liver Cancer Staging (CNLC) Stage : a Propensity Score Matching Study

Acronym: HCC

Important dates

Study start
2019
Primary completion
2023
Study completion
2023
First posted
Apr 30, 2024
Registry last updated
Apr 30, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.